Cyproheptadine/prazosin

Cyproheptadine/prazosin
Cyproheptadine
Prazosin
Combination of
CyproheptadineSerotonin 5-HT2 receptor antagonist, other actions
Prazosinα1-Adrenergic receptor antagonist
Clinical data
Other namesPeriactin/Alpress; KT-110; KT110
Routes of
administration		Unspecified[1]

Cyproheptadine/prazosin, also known by its developmental code name KT-110, is a combination of cyproheptadine, an antihistamine and serotonin 5-HT2 receptor antagonist among other actions, and prazosin, an α1-adrenergic receptor antagonist, which is under development for the treatment of alcoholism, cocaine-related disorders, post-traumatic stress disorder (PTSD), and substance-related disorders.[1][2][3] Its route of administration is unspecified.[1]

The drug is thought to work for treatment of drug addiction via simultaneous blockade of the serotonin 5-HT2A receptor and the α1B-adrenergic receptor, which is thought to strongly reduce dopamine elevations and associated effects like behavioral sensitization in response to drugs of misuse like stimulants, opioids, and alcohol.[3][4][5][6] Whereas cyproheptadine or prazosin alone had no effect on alcohol preference in rodents, the combination of cyproheptadine and prazosin reduced alcohol preference.[3]

Cyproheptadine/prazosin was originated by Greenpharma SAS and Key-Obs and is under development by Kinnov Therapeutics.[1][2] As of March 2025, it is in phase 2 clinical trials for alcoholism and the preclinical research stage of development for cocaine-related disorders and PTSD, whereas no recent development has been reported for substance-related disorders (reached preclinical).[1][2]

See also

References

  1. 1 2 3 4 5 "Cyproheptadine/Prazosin". AdisInsight. 27 March 2025. Retrieved 2 June 2026.
  2. 1 2 3 "Delving into the Latest Updates on Cyproheptadine Hydrochloride/Prazosin Hydrochloride with Synapse". Synapse. 13 December 2025. Retrieved 2 June 2026.
  3. 1 2 3 Aubin HJ, Berlin I, Guiraud J, Bruhwyler J, Batel P, Perney P, et al. (July 2024). "Prazosin and cyproheptadine in combination in the treatment of alcohol use disorder: A randomized, double-blind, placebo-controlled trial". Addiction. 119 (7): 1211–1223. doi:10.1111/add.16484. PMID 38597214.
  4. ↑ Auclair A, Drouin C, Cotecchia S, Glowinski J, Tassin JP (December 2004). "5-HT2A and alpha1b-adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants". The European Journal of Neuroscience. 20 (11): 3073–3084. doi:10.1111/j.1460-9568.2004.03805.x. PMID 15579162.
  5. ↑ Trovero F, David S, Bernard P, Puech A, Bizot JC, Tassin JP (2016). "The Combination of Marketed Antagonists of α1b-Adrenergic and 5-HT2A Receptors Inhibits Behavioral Sensitization and Preference to Alcohol in Mice: A Promising Approach for the Treatment of Alcohol Dependence". PLOS ONE. 11 (3) e0151242. doi:10.1371/journal.pone.0151242. PMC 4788426. PMID 26968030.
  6. ↑ Auclair A, Blanc G, Glowinski J, Tassin JP (October 2004). "Role of serotonin 2A receptors in the D-amphetamine-induced release of dopamine: comparison with previous data on alpha1b-adrenergic receptors". Journal of Neurochemistry. 91 (2): 318–326. doi:10.1111/j.1471-4159.2004.02714.x. PMID 15447665.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.